We are live on ! Find out more
IBO icon

Impact BioMedical
IBO

Delisted

IBO was delisted on the 17th of November, 2026.

19 hedge funds and large institutions have $1.71M invested in Impact BioMedical in 2026 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 4

22% more capital inflows, than outflows

Capital inflows: $60.8K | Capital outflows: $50K

0.02% more ownership

Funds ownership: 3.56% → 3.58% (+0.02%)

5% less funds holding

Funds holding: 20 → 19 (-1)

20% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 5

Holders
19
Holders Change
-1
Holders Change %
-5%
% of All Funds
0.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
6
Reduced
4
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

IBO Hedge Fund Activity: Q3 2026 in Review

19 of the 8,224 institutional investors tracked by Wall St. Rank reported a position in Impact BioMedical (IBO) for Q3 2026, worth a combined $1.71M — down 3% from $1.76M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of IBO and 4 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 6 added.

The largest buyer was Vanguard Capital Management, adding an estimated $56.6K. The largest seller was Citadel Advisors, exiting entirely with an estimated $22.8K sold.

  • 19 institutional investors held Impact BioMedical (IBO) as of Q3 2026, down from 20 in Q2 2026.
  • Funds reported $1.71M of Impact BioMedical stock for Q3 2026, down 3% quarter-over-quarter.
  • 4 funds opened new Impact BioMedical positions in Q3 2026 and 5 closed out, a net change of -1 holder.
  • The largest Impact BioMedical buyer in Q3 2026 was Vanguard Capital Management, an estimated $56.6K added.
  • The largest Impact BioMedical seller in Q3 2026 was Citadel Advisors, an estimated $22.8K sold.

Based on aggregated 13F filings for Q3 2026.